Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | SORD | Q00796 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21268948 | 0.82 | F10 (0.37) | F10PARP1SORDHRH3SSTR3 | |
| SCHEMBL22822852 | 0.82 | F10 (0.37) | F10PARP1SORDHRH3SSTR3 | |
| SCHEMBL22801956 | 0.76 | F10 (0.38) | F10PARP1 | |
| SCHEMBL21268772 | 0.76 | F10 (0.39) | F10PARP1SORDNPC1RAB9A | |
| SCHEMBL21285573 | 0.76 | F10 (0.41) | F10PARP1SORDNPC1RAB9A | |
| SCHEMBL21274174 | 0.76 | F10 (0.37) | F10PARP1SORDHRH3HRH4 | |
| SCHEMBL21268750 | 0.76 | F10 (0.39) | F10PARP1HRH3HRH4FLT1 | |
| SCHEMBL21274039 | 0.75 | F10 (0.35) | F10PARP1 | |
| SCHEMBL22801910 | 0.75 | F10 (0.35) | F10PARP1 | |
| SCHEMBL22756578 | 0.70 | HTR3E (0.45) | F10HRH4FLT1CDK8CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | F10 4164/4885PARP1 158/4885SORD 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.